Small Cap Feast
Small Cap Feast – 11 December 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp):
Total number of AIM Companies trading: *
* As at
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): *
Total number of NEX Growth Market Companies trading: *
* As at
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): *
Total number of Standard List Companies trading: *
* As at
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
MJ Hudson Group PLC, the financial services support provider to Alternatives fund managers and asset owners, is planning an AIM IPO. Deal details TBC.
Adriatic Metals. ASX Listed seeking dual listing in London. Due 12 Dec
SulNOx Group – The Group has developed a methodology and process capable of emulsifying hydrocarbon fuels such as diesel and heavy fuel oil . By January 2014, following preliminary laboratory testing, SulNOx was in a position to suggest that its products resulted in up to a 50% reduction of Nitrogen Oxide (NOx) and a 90% reduction in particulate matter Due 17 Dec, mkt cap £42.3m.
Team 17 (TM17.L) 309p £406m
The “global games label, creative partner and developer of independent (“indie”), premium video games, is pleased to announce that The Survivalists will launch in 2020.
Developed internally, and set in The Escapists’ universe, the survival-lite sandbox game will launch on Nintendo Switch™, PlayStation 4, Xbox One and PC.
The Survivalists sees players shipwrecked on procedurally-generated islands and combines the crafting, combat and building elements of The Escapists with new features including a mimic system that allows players to train monkeys, gather resources, build structures and fight off threats. In addition to single-player mode, the game will also feature a session-based, online co-operative multiplayer element, as introduced in The Escapists 2.”
Amino Technologies (AMO.L) 106p £80.6m
The technology provider for modern TV experiences, announces that 24i, the Group’s global video experience business, has launched a new suite of applications and Subscription Video-On-Demand (SVOD) services for US-based video streaming service BroadwayHD.
24i’s capacity to create next-generation, branded video experiences and applications, has provided BroadwayHD with a robust end-to-end OTT video solution that accelerates growth by providing subscribers with a rich, personalized and easy to navigate experience on any device.
BroadwayHD offers subscribers unlimited on-demand access to a library of more than 250 theatre productions from Broadway, The West End and beyond. The premier streaming service is available online at broadwayhd.com, and via a dedicated app on iOS, Android, Apple TV, Amazon Firestick and Roku.
Sopheon (SPE.L) 690p £62.2m
“In our interim results statement issued on 22 August 2019, we noted that we expected a more pronounced second half weighting to our annual performance, alongside a significantly expanded sales pipeline with a much higher than expected proportion of SaaS opportunities. That expectation has not changed. We entered the traditionally busy final quarter with over $30m1 in opportunities with 2019 target close dates, of which almost half related to SaaS deals and the balance in perpetual licenses along with associated consulting services. Today, overall revenue visibility2 for the year stands at $28m with $9.9m in remaining opportunities with 2019 target close dates. Of this, up to $2.7m represents perpetual license fees which, if signed, would contribute to recognized revenue in the current financial year. An additional $4.8m represents potential orders for multi-year SaaS or other recurring commitments, and the balance associated consulting services. December is traditionally a very busy month where we would expect to close a material number of deals and this would deliver a strong quarter in historic terms; however we would caution that our ability to execute on this is dependent on customers signing orders consistent with their plans”.
Europa Oil & Gas (EOG.L) 1.75p £7.8m
AGM Statement. “The opening sentence of Europa Oil and Gas press releases describes us as an exploration and production company. The exploration side is largely accounted for by a very high impact portfolio of offshore Ireland licences which combined have the potential to host gross mean un-risked prospective resources of 6.4 billion barrels oil equivalent and 1.5 tcf gas. The production side of the business is comprised of interests in three onshore fields in the U.K. East Midlands which, over the course of the last financial year, produced 91 boepd net to Europa and generated £1.7 million revenues. Like all E&P companies, our aim is to move assets from exploration towards production via success with the drill bit, thereby scaling up revenues, increasing reserves and generating value for shareholders.”
In terms of appraisal, the results of the public enquiry into the Wressle field are due post election. A positive result would have a dramatic effect on the Company’s production profile.
Lightwave RF (LWRF.L) 4.05p £5m
Update for October and November. Like-for-like sales for the Period were up 12% on the corresponding period last year at £815,000. Direct sales demonstrated a record performance for the Black Friday and Cyber Monday period, which ran from 25 November 2019 to 2 December 2019, with sales up 23% on the corresponding period last year to £252,000 comprising: Telesales increased by 57% to £118,000 ); & E-commerce sales increased by 3% to £134,000. As announced on 4 November 2019, whilst substantial progress was made in annual revenue growth in the Company’s last financial year, the final quarter was held back by a number of one-off issues. Trading during demonstrates a return to the sales levels experienced during the first three quarters of FY 2019. The Company is currently conducting a formal review of the various strategic options, including a potential sale of the Company .
Faron Pharma (FARN.L) 301p £130m
New data from MATINS -trial patients to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland. Faron’s scientific network will present the data in a plenary lecture and more detailed biomarker data in a Mini Oral session. First available set of cell surface biomarker data from a group of seven patients to be presented at the congress show that: 1) anti-Clever-1 treatment in cancer patients decreases a broad range of checkpoints including PD-1, PD-L1, CTLA-4, OX40, 41BB, LAG3 and 2) co-stimulation markers CD28 and ICOS on circulating T cell populations whereas 3) it increases the expression of activation markers CD25 (IL-2RA), CXCR3 and CD69. In addition, anti-tumour responses with anti-Clever-1 treatment are found to associate with an increase in plasma interferon gamma (IFN-gamma), which is one of the tools the immune system is using to fight against cancer.
Minoan Group (MIN.L) 2.2p £9.4m
“Minoan’s Board has been actively exploring interest from a range of serious parties operating within inter alia, the UK, the Middle and Far East as well as Greece. The Board is now considering a number of different types of commercial transactions with a view to entering into more formal arrangements. Whilst there can be no guarantee, we expect to be able to confirm and move forward with the most appropriate transaction in the first quarter of the New Year. We will keep the market informed on progress.” onclusion of the Firm Subscription for cash referred to in its announcement on the 10 May 2019 as a result of which, the Company has issued a further 7,272,728 ordinary shares of 1p each (“New Ordinary Shares”) at 2.75p per share.
In addition, the Company has agreed to settle certain liabilities by the issue of 8,494,603 Ordinary Shares of 1p each at 2.75p per share.
Pelatro (PTRO.L) 55p £18m
The global Multichannel Marketing Hub software specialist, is pleased to announce another contract win that further establishes its position in the industry as a company with significant domain expertise to assist telcos in their campaign management activities.
The Group has been selected by one of its existing customers in Asia to provide Business Consultancy for the campaign management activities of the telco.
The revenue potential to Pelatro is about US$ 1 million over three years.
Karelian Diamonds (KDR.L) 2.9p £1.16m
Karelian has raised a total of £240,000 through a subscription in the capital of the Company and the issue of an unsecured convertible loan note. Subscription price 4p. Conversion Price 10p.
The deal has been subscribed for by a new investor, Fredrik Björnberg. Mr. Björnberg is a member of a prominent family in Finland with a range of business activities, in particular in the forestry and paper industry.
The Björnberg family previously owned the Luikonlahti copper mine in the Kaavi area and still have close connections with this part of Finland.
Provexis (PXS.L) 0.45p £8.8m
“Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, is pleased to announce it has raised a gross £301,333 via a placing (the ‘Placing’), conditional on admission to trading on AIM, of 75,333,333 new ordinary shares of 0.1p each (the ‘New Provexis Shares’) with new and existing investors.” Priced at 0,4p an 11.1% discount to yesterday’s close.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.